Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: A systematic review and meta-analysis

BMJ Open

Volumn 6, Issue 3, 2016, Pages

  Dautzenberg, M J D ^a   Haverkate, M R ^a   Bonten, M J M ^a   Bootsma, M C J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLONE; DISEASE DURATION; EPIDEMIC; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; NONHUMAN; PREVALENCE; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; META ANALYSIS; MICROBIAL SENSITIVITY TEST; PATHOGENICITY;

EPIDEMICS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84962328254     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009971     Document Type: Article

References (246)

1. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25: H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008;61:273-81.
2. Samuelsen Ø, Naseer U, Tofteland S, et al. Emergence of clonally related Klebsiella isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. J Antimicrob Chemother 2009;63:654-8.
3. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an Intriguing Clonal Group. Clin Microbiol Rev 2014;27:543-74.
4. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: A pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011;66:1-14.
5. Banerjee R, Johnson JR. A new clone sweeps clean: The enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother 2014;58:4997-5004.
6. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: The role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011;35:736-55.
7. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: Clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009;53:3365-70.
8. Grundmann H, Livermore DM, Giske CG, et al., CNSE Working Group. Carbapenem-non-susceptible Enterobacteriaceae in Europe: Conclusions from a meeting of national experts. Euro Surveill 2010;15:pii: 19711. http://www.ncbi.nlm.nih.gov/pubmed/ 21144429 (accessed 20 May 2015).
9. Rogers BA, Doi Y. Who is leading this dance? Understanding the spread of Escherichia coli sequence type 131. Infect Control Hosp Epidemiol 2013;34:370-2.
10. Bonten MJ, Weinstein RA. The role of colonization in the pathogenesis of nosocomial infections. Infect Control Hosp Epidemiol 1996;17:193-200.
11. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12. http://www.ncbi.nlm.nih.gov/ pubmed/10789670 (accessed 28 Mar 2015).
12. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
13. Veenemans J, Overdevest IT, Snelders E, et al. Next-generation sequencing for typing and detection of resistance genes: Performance of a new commercial method during an outbreak of extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 2014;52:2454-60.
14. Kojima Y, Harada S, Aoki K, et al. Spread of CTX-M-15 extended-spectrum ß-lactamase-producing Escherichia coli isolates through household contact and plasmid transfer. J Clin Microbiol 2014;52:1783-5.
15. Blanc V, Leflon-Guibout V, Blanco J, et al. Prevalence of day-care centre children (France) with faecal CTX-M-producing Escherichia coli comprising O25b:H4 and O16:H5 ST131 strains. J Antimicrob Chemother 2014;69:1231-7.
16. Giuffr? M, Cipolla D, Bonura C, et al. Outbreak of colonizations by extended-spectrum ß-lactamase-producing Escherichia coli sequence type 131 in a neonatal intensive care unit, Italy. Antimicrob Resist Infect Control 2013;2:8.
17. Adler A, Gniadkowski M, Baraniak A, et al. Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre. Clin Microbiol Infect 2012;18:E497-505.
18. Hilty M, Betsch BY, Bfgli-Stuber K, et al. Transmission dynamics of extended-spectrum ß-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis 2012;55:967-75.
19. Owens RC, Johnson JR, Stogsdill P, et al. Community transmission in the United States of a CTX-M-15-producing sequence type ST131 Escherichia coli strain resulting in death. J Clin Microbiol 2011;49:3406-8.
20. Johnson JR, Anderson JT, Clabots C, et al. Within-household sharing of a fluoroquinolone-resistant Escherichia coli sequence type ST131 strain causing pediatric osteoarticular infection. Pediatr Infect Dis J 2010;29:473-5.
21. Ender PT, Gajanana D, Johnston B, et al. Transmission of an extended-spectrum-beta-lactamase-producing Escherichia coli (sequence type ST131) strain between a father and daughter resulting in septic shock and Emphysematous pyelonephritis. J Clin Microbiol 2009;47:3780-2.
22. Marquez C, Ingold A, Echeverría N, et al. Emergence of KPC-producing Klebsiella pneumoniae in Uruguay: Infection control and molecular characterization. New microbes new Infect 2014;2:58-63.
23. Garza-Ramos U, Barrios H, Reyna-Flores F, et al. Characteristics of KPC-2-producing Klebsiella pneumoniae (ST258) clinical isolates from outbreaks in 2 Mexican medical centers. Diagn Microbiol Infect Dis 2014;79:483-5.
24. Gaibani P, Colombo R, Arghittu M, et al. Successful containment and infection control of a Carbapenem-resistant Klebsiella pneumoniae outbreak in an Italian hospital. New Microbiol 2014;37:87-90. http://www.ncbi.nlm.nih.gov/pubmed/24531175 (accessed 20 May 2015).
25. Giuffrè M, Bonura C, Geraci DM, et al. Successful control of an outbreak of colonization by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae sequence type 258 in a neonatal intensive care unit, Italy. J Hosp Infect 2013;85:233-6.
26. Tofteland S, Naseer U, Lislevand JH, et al. A long-term low-frequency hospital outbreak of KPC-producing Klebsiella pneumoniae involving Intergenus plasmid diffusion and a persisting environmental reservoir. PLoS ONE 2013;8:e59015.
27. Morris D, Boyle F, Morris C, et al. Inter-hospital outbreak of Klebsiella pneumoniae producing KPC-2 carbapenemase in Ireland. J Antimicrob Chemother 2012;67:2367-72.
28. Agodi A, Voulgari E, Barchitta M, et al. Containment of an outbreak of KPC-3-producing Klebsiella pneumoniae in Italy. J Clin Microbiol 2011;49:3986-9.
29. Won SY, Munoz-Price LS, Lolans K, et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011;53:532-40.
30. Marchese A, Coppo E, Barbieri R, et al. Emergence of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains and spread of an isolate of sequence type 258 in the neuro-rehabilitation unit of an Italian hospital. J Chemother 2010;22:212-14.
31. Mammina C, Palma DM, Bonura C, et al. Outbreak of infection with Klebsiella pneumoniae sequence type 258 producing Klebsiella pneumoniae Carbapenemase 3 in an intensive care unit in Italy. J Clin Microbiol 2010;48:1506-7.
32. Titelman E, Hasan CM, Iversen A, et al. Faecal carriage of extended-spectrum ß-lactamase-producing Enterobacteriaceae is common 12 months after infection and is related to strain factors. Clin Microbiol Infect 2014;20:O508-15.
33. Rogers BA, Kennedy KJ, Sidjabat HE, et al. Prolonged carriage of resistant E. coli by returned travellers: Clonality, risk factors and bacterial characteristics. Eur J Clin Microbiol Infect Dis 2012;31:2413-20.
34. Papagiannitsis CC, Študentová V, Jakubu V, et al. High prevalence of ST131 among CTX-M-producing Escherichia coli from community-acquired infections, in the Czech Republic. Microb Drug Resist 2015;21:74-84.
35. Osawa K, Shigemura K, Shimizu R, et al. Molecular characteristics of extended-spectrum ß-lactamase-producing Escherichia coli in a university teaching hospital. Microb Drug Resist 2015;21:130-9.
36. Hristea A, Olaru ID, Adams-Sapper S, et al. Characterization of ESBL-producing Escherichia coli and Klebsiella pneumoniae from bloodstream infections in three hospitals in Bucharest, Romania: A preliminary study. Infect Dis (Lond) 2015;47:46-51.
37. Salipante SJ, Roach DJ, Kitzman JO, et al. Large-scale genomic sequencing of extraintestinal pathogenic Escherichia coli strains. Genome Res 2015;25:119-28.
38. Can F, Azap OK, Seref C, et al. Emerging Escherichia coli O25b/ ST131 clone predicts treatment failure in urinary tract infections. Clin Infect Dis 2015;60:523-7.
39. Zhao L, Zhang J, Zheng B, et al. Molecular epidemiology and genetic diversity of fluoroquinolone-resistant Escherichia coli isolates from patients with community-onset infections in 30 Chinese county hospitals. J Clin Microbiol 2015;53:766-70.
40. Hansen F, Olsen SS, Heltberg O, et al. Characterization of third-generation cephalosporin-resistant Escherichia coli from bloodstream infections in Denmark. Microb Drug Resist 2014;20:316-24.
41. Berman H, Barberino MG, Moreira ED, et al. Distribution of strain type and antimicrobial susceptibility of Escherichia coli isolates causing meningitis in a large urban setting in Brazil. J Clin Microbiol 2014;52:1418-22.
42. Peirano G, Pitout JDD. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a Canadian region with a centralized laboratory system: Rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother 2014;58:2699-703.
43. Shakir SM, Goldbeck JM, Robison D, et al. Genotypic and phenotypic characterization of invasive neonatal Escherichia coli clinical isolates. Am J Perinatol 2014;31:975-82.
44. Peirano G, Ahmed-Bentley J, Fuller J, et al. Travel-related carbapenemase-producing Gram-negative bacteria in Alberta, Canada: The first 3 years. J Clin Microbiol 2014;52:1575-81.
45. Sana F, Mabrouka S, Claudine Q, et al. Prevalence and characterization of uropathogenic Escherichia coli harboring plasmid-mediated quinolone resistance in a Tunisian university hospital. Diagn Microbiol Infect Dis 2014;79:247-51.
46. Önnberg A, Söderquist B, Persson K, et al. Characterization of CTX-M-producing Escherichia coli by repetitive sequence-based PCR and real-time PCR-based replicon typing of CTX-M-15 plasmids. APMIS 2014;122:1136-43.
47. Oteo J, González-López JJ, Ortega A, et al, Spanish Network for Research in Infectious Diseases (REIPI). Inhibitor-resistant TEMand OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates. Antimicrob Agents Chemother 2014;58:3874-81.
48. Rodríguez I, Thomas K, Van Essen A, et al. Chromosomal location of blaCTX-M genes in clinical isolates of Escherichia coli from Germany, The Netherlands and the UK. Int J Antimicrob Agents 2014;43:553-7.
49. O'Hara JA, Hu F, Ahn C, et al. Molecular epidemiology of KPC-producing Escherichia coli: Occurrence of ST131-fimH30 subclone harboring pKpQIL-like IncFIIk plasmid. Antimicrob Agents Chemother 2014;58:4234-7.
50. Inwezerua C, Mendonça N, Calhau V, et al. Occurrence of extended-spectrum beta-lactamases in human and bovine isolates of Escherichia coli from Oyo state, Nigeria. J Infect Dev Ctries 2014;8:774-9. http://www.ncbi.nlm.nih.gov/pubmed/24916877 (accessed 2 Nov 2015).
51. Micenková L, Sišková P, Bosák J, et al. Characterization of Human Uropathogenic ESBL-Producing Escherichia coli in the Czech Republic: Spread of CTX-M-27-Producing Strains in a University Hospital. Microb Drug Resist 2014;20:610-17.
52. Xia S, Fan X, Huang Z, et al. Dominance of CTX-M-type extended-spectrum ß-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS ONE 2014;9:e100707.
53. Morgand M, Vimont S, Bleibtreu A, et al. Extended-spectrum beta-lactamase-producing Escherichia coli infections in children: Are community-acquired strains different from nosocomial strains? Int J Med Microbiol 2014;304:970-6.
54. Suwantarat N, Rudin SD, Marshall SH, et al. Infections caused by fluoroquinolone-resistant Escherichia coli following transrectal ultrasound-guided biopsy of the prostate. J Glob Antimicrob Resist 2014;2:71-6.
55. Maluta RP, Logue CM, Casas MRT, et al. Overlapped sequence types (STs) and serogroups of avian pathogenic (APEC) and human extra-intestinal pathogenic (ExPEC) Escherichia coli isolated in Brazil. PLoS ONE 2014;9:e105016.
56. Dashti AA, Vali L, El-Shazly S, et al. The characterization and antibiotic resistance profiles of clinical Escherichia coli O25b-B2-ST131 isolates in Kuwait. BMC Microbiol 2014; 14:214.
57. Freeman JT, Rubin J, McAuliffe GN, et al. Differences in risk-factor profiles between patients with ESBL-producing Escherichia coli and Klebsiella pneumoniae: A multicentre case-case comparison study. Antimicrob Resist Infect Control 2014;3:27.
58. Hussain A, Ranjan A, Nandanwar N, et al. Genotypic and phenotypic profiles of Escherichia coli isolates belonging to clinical sequence type 131 (ST131), clinical non-ST131, and fecal non-ST131 lineages from India. Antimicrob Agents Chemother 2014;58:7240-9.
59. Dahbi G, Mora A, Mamani R, et al. Molecular epidemiology and virulence of Escherichia coli O16:H5-ST131: Comparison with H30 and H30-Rx subclones of O25b:H4-ST131. Int J Med Microbiol 2014;304:1247-57.
60. Zhang J, Zheng B, Zhao L, et al. Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals. BMC Infect Dis 2014;14:659.
61. Usein CR, Condei M, Cristea D, et al. Escherichia coli ST131 causing invasive infections in Romanian patients-A threat we can no longer ignore. Roum Arch Microbiol Immunol 2014;73:5-8. http://www.ncbi.nlm.nih.gov/pubmed/25518564 (accessed 23 Nov 2015).
62. Wu YH, Cheng MF, Lai CH, et al. The role of Sequence Type (ST) 131 in adult community-onset non-ESBL-producing Escherichia coli bacteraemia. BMC Infect Dis 2014;14:579.
63. Guillard T, Bertrand X, de Champs C, et al. Aac(6')lb-cr is the major plasmid-mediated quinolone resistance determinant in extended-spectrum beta-lacatamase-producing Escherichia coli in Eastern France. J Global Antimicrob Resist 2014;2:111-13.
64. Habeeb MA, Haque A, Iversen A, et al. Occurrence of virulence genes, 16S rRNA methylases, and plasmid-mediated quinolone resistance genes in CTX-M-producing Escherichia coli from Pakistan. Eur J Clin Microbiol Infect Dis 2014;33:399-409.
65. López-Cerero L, Navarro MD, Bellido M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ ST131: Risk factors and clinical implications. J Antimicrob Chemother 2014;69:809-14.
66. Giufre M, Accogli M, Farina C, et al. Predominance of the fimH30 subclone among multidrug-resistant Escherichia coli strains belonging to sequence type 131 in Italy. J Infect Dis 2014;209:629-30.
67. Ferjani S, Saidani M, Ennigrou S, et al. Multidrug resistance and high virulence genotype in uropathogenic Escherichia coli due to diffusion of ST131 clonal group producing CTX-M-15: An emerging problem in a Tunisian hospital. Folia Microbiol (Praha) 2014;59:257-62.
68. Al-Agamy MH, Shibl AM, Hafez MM, et al. Molecular characteristics of extended-spectrum ß-lactamase-producing Escherichia coli in Riyadh: Emergence of CTX-M-15-producing E. coli ST131. Ann Clin Microbiol Antimicrob 2014;13:4.
69. Rogers BA, Ingram PR, Runnegar N, et al. Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries. Antimicrob Agents Chemother 2014;58:2126-34.
70. Nicolas-Chanoine MH, Robert J, Vigan M, et al. Different factors associated with CTX-M-producing ST131 and non-ST131 Escherichia coli clinical isolates. PLoS ONE 2013;8:e72191.
71. Nordberg V, Quizhpe Peralta A, Galindo T, et al. High proportion of intestinal colonization with successful epidemic clones of ESBL-producing Enterobacteriaceae in a neonatal intensive care unit in Ecuador. PLoS ONE 2013;8:e76597.
72. Dimude JU, Amyes SGB. Molecular diversity associated with the dissemination of CTX-M-15 beta-lactamase gene in blood culture isolates of Escherichia coli from Edinburgh. Scand J Infect Dis 2013;45:32-7.
73. Karfunkel D, Carmeli Y, Chmelnitsky I, et al. The emergence and dissemination of CTX-M-producing Escherichia coli sequence type 131 causing community-onset bacteremia in Israel. Eur J Clin Microbiol Infect Dis 2013;32:513-21.
74. Nielsen JB, Albayati A, Jrgensen RL, et al. An abbreviated MLVA identifies Escherichia coli ST131 as the major extended-spectrum ß-lactamase-producing lineage in the Copenhagen area. Eur J Clin Microbiol Infect Dis 2013;32:431-6.
75. van der Donk CFM, Schols JMGA, Driessen CJ, et al. Prevalence and spread of multidrug resistant Escherichia coli isolates among nursing home residents in the southern part of The Netherlands. J Am Med Dir Assoc 2013;14:199-203.
76. Adams-Sapper S, Diep BA, Perdreau-Remington F, et al. Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother 2013;57:490-7.
77. Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum ß-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013;56:641-8.
78. López-Cerero L, Bellido Mdel M, Serrano L, et al. Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enferm Infecc Microbiol Clin 2013;31:385-8.
79. Helldal L, Karami N, Flor?n K, et al. Shift of CTX-M genotypes has determined the increased prevalence of extended-spectrum ß-lactamase-producing Escherichia coli in south-western Sweden. Clin Microbiol Infect 2013;19:E87-90.
80. Hammami S, Saidani M, Ferjeni S, et al. Characterization of extended spectrum ß-lactamase-producing Escherichia coli in community-acquired urinary tract infections in Tunisia. Microb Drug Resist 2013;19:231-6.
81. Kudinha T, Johnson JR, Andrew SD, et al. Distribution of phylogenetic groups, sequence type ST131, and virulence-associated traits among Escherichia coli isolates from men with pyelonephritis or cystitis and healthy controls. Clin Microbiol Infect 2013;19:E173-80.
82. Kudinha T, Johnson JR, Andrew SD, et al. Genotypic and phenotypic characterization of Escherichia coli isolates from children with urinary tract infection and from healthy carriers. Pediatr Infect Dis J 2013;32:543-8.
83. Weissman SJ, Adler A, Qin X, et al. Emergence of extended-spectrum ß-lactam resistance among Escherichia coli at a US academic children's hospital is clonal at the sequence type level for CTX-M-15, but not for CMY-2. Int J Antimicrob Agents 2013;41:414-20.
84. Banerjee R, Johnston B, Lohse C, et al. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol 2013;34:361-9.
85. Kim B, Kim J, Seo MR, et al. Clinical characteristics of communityacquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 2013;41:603-12.
86. Aoike N, Saga T, Sakata R, et al. Molecular characterization of extraintestinal Escherichia coli isolates in Japan: Relationship between sequence types and mutation patterns of quinolone resistance-determining regions analyzed by pyrosequencing. J Clin Microbiol 2013;51:1692-8.
87. Olesen B, Hansen DS, Nilsson F, et al. Prevalence and characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-producing E. coli isolates in Copenhagen, Denmark. J Clin Microbiol 2013;51:1779-85.
88. Qin X, Hu F, Wu S, et al. Comparison of adhesin genes and antimicrobial susceptibilities between uropathogenic and intestinal commensal Escherichia coli strains. PLoS ONE 2013;8:e61169.
89. Denisuik AJ, Lagac?-Wiens PR, Pitout JD, et al., Canadian Antimicrobial Resistance Alliance. Molecular epidemiology of extended-spectrum ß-lactamase-, AmpC ß-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother 2013;68(Suppl 1): I57-65.
90. Yano H, Uemura M, Endo S, et al. Molecular characteristics of extended-spectrum ß-lactamases in clinical isolates from Escherichia coli at a Japanese tertiary hospital. PLoS ONE 2013;8: E64359.
91. Chmielarczyk A, Pobiega M, Wójkowska-Mach J, et al. Molecular epidemiology, plasmid analysis, virulence, and resistance of Escherichia coli isolated from neonatal intensive care units in Poland. Diagn Microbiol Infect Dis 2013;76:542-5.
92. Seiffert SN, Hilty M, Kronenberg A, et al. Extended-spectrum cephalosporin-resistant Escherichia coli in community, specialized outpatient clinic and hospital settings in Switzerland. J Antimicrob Chemother 2013;68:2249-54.
93. Reyna-Flores F, Barrios H, Garza-Ramos U, et al. Molecular epidemiology of Escherichia coli O25b-ST131 isolates causing community-acquired UTIs in Mexico. Diagn Microbiol Infect Dis 2013;76:396-8.
94. Mnif B, Harhour H, Jdidi J, et al. Molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli in Tunisia and characterization of their virulence factors and plasmid addiction systems. BMC Microbiol 2013;13:147.
95. Williamson DA, Freeman JT, Porter S, et al. Clinical and molecular correlates of virulence in Escherichia coli causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. J Antimicrob Chemother 2013;68:2898-906.
96. Kang CI, Cha MK, Kim SH, et al. Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum ß-lactamase-producing Escherichia coli over a 6-year period. J Korean Med Sci 2013;28:998-1004.
97. Kudinha T, Johnson JR, Andrew SD, et al. Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women. J Clin Microbiol 2013;51:3270-6.
98. Hu YY, Cai JC, Zhou HW, et al. Molecular typing of CTX-M-producing escherichia coli isolates from environmental water, swine feces, specimens from healthy humans, and human patients. Appl Environ Microbiol 2013;79:5988-96.
99. van der Donk C, van de Bovenkamp J, Bamelis H, et al. Prevalence and spread of multidrug-resistant Escherichia coli including ST131 in different patient populations in the Euroregion Meuse-Rhine. Future Microbiol 2013;8:1027-37.
100. Banerjee R, Strahilevitz J, Johnson JR, et al. Predictors and molecular epidemiology of community-onset extended-spectrum ß-lactamase-producing Escherichia coli infection in a Midwestern community. Infect Control Hosp Epidemiol 2013;34:947-53.
101. Blanco J, Mora A, Mamani R, et al. Four main virotypes among extended-spectrum-ß-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: Bacterial, epidemiological, and clinical characteristics. J Clin Microbiol 2013;51:3358-67.
102. Colpan A, Johnston B, Porter S, et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013;57:1256-65.
103. Dahbi G, Mora A, Lspez C, et al. Emergence of new variants of ST131 clonal group among extraintestinal pathogenic Escherichia coli producing extended-spectrum ß-lactamases. Int J Antimicrob Agents 2013;42:347-51.
104. Horner C, Fawley W, Morris K, et al. Escherichia coli bacteraemia: 2 years of prospective regional surveillance (2010-12). J Antimicrob Chemother 2014;69:91-100.
105. Banerjee R, Johnston B, Lohse C, et al. The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics. Antimicrob Agents Chemother 2013;57:5912-17.
106. Ha YE, Kang CI, Cha MK, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum ß-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents 2013;42:403-9.
107. Brolund A, Edquist PJ, Mdkitalo B, et al. Epidemiology of extended-spectrum ß-lactamase-producing Escherichia coli in Sweden 2007-2011. Clin Microbiol Infect 2014;20:O344-52.
108. Aschbacher R, Giani T, Corda D, et al. Carbapenemase-producing Enterobacteriaceae during 2011-12 in the Bolzano area (Northern Italy): Increasing diversity in a low-endemicity setting. Diagn Microbiol Infect Dis 2013;77:354-6.
109. Calhau V, Ribeiro G, Mendonça N, et al. Prevalent combination of virulence and plasmidic-encoded resistance in ST 131 Escherichia coli strains. Virulence 2013;4:726-9.
110. Markovska R, Schneider I, Ivanova D, et al. Predominance of IncL/ M and IncF plasmid types among CTX-M-ESBL-producing Escherichia coli and Klebsiella pneumoniae in Bulgarian hospitals. APMIS 2014;122:608-15.
111. Ma L, Siu LK, Lin JC, et al. Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: First identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC Infect Dis 2013;13:599.
112. Brisse S, Diancourt L, Laou?nan C, et al. Phylogenetic distribution of CTX-M- and non-extended-spectrum-ß-lactamase-producing Escherichia coli isolates: Group B2 isolates, except clone ST131, rarely produce CTX-M enzymes. J Clin Microbiol 2012;50:2974-81.
113. Weissman SJ, Johnson JR, Tchesnokova V, et al. High-resolution two-locus clonal typing of extraintestinal pathogenic Escherichia coli. Appl Environ Microbiol 2012;78:1353-60.
114. Musumeci R, Rausa M, Giovannoni R, et al. Prevalence of plasmid-mediated quinolone resistance genes in uropathogenic Escherichia coli isolated in a teaching hospital of northern Italy. Microb Drug Resist 2012;18:33-41.
115. Oteo J, Cercenado E, Fernandez-Romero S, et al. Extended-spectrum-ß-lactamase-producing Escherichia coli as a cause of pediatric infections: Report of a neonatal intensive care unit outbreak due to a CTX-M-14-producing strain. Antimicrob Agents Chemother 2012;56:54-8.
116. Gibreel TM, Dodgson AR, Cheesbrough J, et al. Population structure, virulence potential and antibiotic susceptibility of uropathogenic Escherichia coli from Northwest England. J Antimicrob Chemother 2012;67:346-56.
117. Chung HC, Lai CH, Lin JN, et al. Bacteremia caused by extended-spectrum-ß-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: Comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 2012;56:618-22.
118. Peirano G, van der Bij AK, Gregson DB, et al. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum ß-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol 2012;50:294-9.
119. Tiruvury H, Johnson JR, Mariano N, et al. Identification of CTX-M ß-lactamases among Escherichia coli from the community in New York City. Diagn Microbiol Infect Dis 2012;72:248-52.
120. Giufrè M, Graziani C, Accogli M, et al. Escherichia coli of human and avian origin: Detection of clonal groups associated with fluoroquinolone and multidrug resistance in Italy. J Antimicrob Chemother 2012;67:860-7.
121. Novais A, Rodrigues C, Branquinho R, et al. Spread of an OmpK36-modified ST15 Klebsiella pneumoniae variant during an outbreak involving multiple carbapenem-resistant Enterobacteriaceae species and clones. Eur J Clin Microbiol Infect Dis 2012;31:3057-63.
122. Matsumura Y, Nagao M, Iguchi M, et al. Molecular and clinical characterization of plasmid-mediated AmpC ß-lactamase-producing Escherichia coli bacteraemia: A comparison with extended-spectrum ß-lactamase-producing and non-resistant E. coli bacteraemia. Clin Microbiol Infect 2013;19:161-8.
123. Yokota S, Sato T, Okubo T, et al. Prevalence of fluoroquinoloneresistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan. Chemotherapy 2012;58:52-9.
124. Johnson JR, Urban C, Weissman SJ, et al., AMERECUS Investigators. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-ß-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 2012;56:2364-70.
125. Williamson DA, Roberts SA, Paterson DL, et al. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: Implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 2012;54:1406-12.
126. Ho PL, Yeung MK, Lo WU, et al. Predominance of pHK01-like incompatibility group FII plasmids encoding CTX-M-14 among extended-spectrum beta-lactamase-producing Escherichia coli in Hong Kong, 1996-2008. Diagn Microbiol Infect Dis 2012;73:182-6.
127. Dimou V, Dhanji H, Pike R, et al. Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. J Antimicrob Chemother 2012;67:1660-5.
128. Burke L, Humphreys H, Fitzgerald-Hughes D. The revolving door between hospital and community: Extended-spectrum beta-lactamase-producing Escherichia coli in Dublin. J Hosp Infect 2012;81:192-8.
129. Park SH, Byun JH, Choi SM, et al. Molecular epidemiology of extended-spectrum ß-lactamase-producing Escherichia coli in the community and hospital in Korea: Emergence of ST131 producing CTX-M-15. BMC Infect Dis 2012;12:149.
130. Reuland EA, Overdevest IT, Al Naiemi N, et al. High prevalence of ESBL-producing Enterobacteriaceae carriage in Dutch community patients with gastrointestinal complaints. Clin Microbiol Infect 2013;19:542-9.
131. Kuroda H, Yano H, Hirakata Y, et al. Molecular characteristics of extended-spectrum ß-lactamase-producing Escherichia coli in Japan: Emergence of CTX-M-15-producing E. coli ST131. Diagn Microbiol Infect Dis 2012;74:201-3.
132. Gibreel TM, Dodgson AR, Cheesbrough J, et al. High metabolic potential May contribute to the success of ST131 uropathogenic Escherichia coli. J Clin Microbiol 2012;50:3202-7.
133. Matsumura Y, Yamamoto M, Nagao M, et al. Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-ß-lactamase-producing Escherichia coli in Japan. J Antimicrob Chemother 2012;67:2612-20.
134. Österblad M, Kirveskari J, Hakanen AJ, et al. Carbapenemase-producing Enterobacteriaceae in Finland: The first years (2008-11). J Antimicrob Chemother 2012;67:2860-4.
135. Naseer U, Olsson-Liljequist BE, Woodford N, et al. Multi-locus variable number of tandem repeat analysis for rapid and accurate typing of virulent multidrug resistant Escherichia coli clones. PLoS ONE 2012;7:e41232.
136. Golding GR, Persaud N, Levett PN, et al. Characterization of Escherichia coli urinary tract infection isolates in remote northern Saskatchewan communities: The Northern Antibiotic Resistance Partnership. Diagn Microbiol Infect Dis 2012;74:242-7.
137. Hussain A, Ewers C, Nandanwar N, et al. Multiresistant uropathogenic Escherichia coli from a region in India where urinary tract infections are endemic: Genotypic and phenotypic characteristics of sequence type 131 isolates of the CTX-M-15 extended-spectrum-ß-lactamase-producing lineage. Antimicrob Agents Chemother 2012;56:6358-65.
138. van der Donk CF, van de Bovenkamp JH, De Brauwer EI, et al. Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine. PLoS ONE 2012;7:e47707.
139. Mavroidi A, Miriagou V, Liakopoulos A, et al. Ciprofloxacin-resistant Escherichia coli in Central Greece: Mechanisms of resistance and molecular identification. BMC Infect Dis 2012;12:371.
140. Peirano G, Asensi MD, Pitondo-Silva A, et al. Molecular characteristics of extended-spectrum ß-lactamase-producing Escherichia coli from Rio de Janeiro, Brazil. Clin Microbiol Infect 2011;17:1039-43.
141. Peirano G, van Greune CH, Pitout JD. Characteristics of infections caused by extended-spectrum ß-lactamase-producing Escherichia coli from community hospitals in South Africa. Diagn Microbiol Infect Dis 2011;69:449-53.
142. Overdevest I, Willemsen I, Rijnsburger M, et al. Extended-spectrum ß-lactamase genes of Escherichia coli in chicken meat and humans, The Netherlands. Emerg Infect Dis 2011;17:1216-22.
143. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J, et al, National ESBL surveillance group. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin Microbiol Infect 2011;17:873-80.
144. Courpon-Claudinon A, Lefort A, Panhard X, et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: Prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect 2011;17:557-65.
145. Rodriguez-Villalobos H, Bogaerts P, Berhin C, et al. Trends in production of extended-spectrum beta-lactamases among Enterobacteriaceae of clinical interest: Results of a nationwide survey in Belgian hospitals. J Antimicrob Chemother 2011;66:37-47.
146. Mora A, Blanco M, López C, et al. Emergence of clonal groups O1: HNM-D-ST59, O15:H1-D-ST393, O20:H34/HNM-D-ST354, O25b: H4-B2-ST131 and ONT:H21,42-B1-ST101 among CTX-M-14-producing Escherichia coli clinical isolates in Galicia, northwest Spain. Int J Antimicrob Agents 2011;37:16-21.
147. Coelho A, Mora A, Mamani R, et al. Spread of Escherichia coli O25b:H4-B2-ST131 producing CTX-M-15 and SHV-12 with high virulence gene content in Barcelona (Spain). J Antimicrob Chemother 2011;66:517-26.
148. Xu L, Shabir S, Bodah T, et al. Regional survey of CTX-M-type extended-spectrum ß-lactamases among Enterobacteriaceae reveals marked heterogeneity in the distribution of the ST131 clone. J Antimicrob Chemother 2011;66:505-11.
149. Ruiz SJ, Montealegre MC, Ruiz-Garbajosa P, et al. First characterization of CTX-M-15-producing Escherichia coli ST131 and ST405 clones causing community-onset infections in South America. J Clin Microbiol 2011;49:1993-6.
150. Simner PJ, Zhanel GG, Pitout J, et al. Prevalence and characterization of extended-spectrum ß-lactamase- and AmpC ß-lactamase-producing Escherichia coli: Results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011;69:326-34.
151. Dhanji H, Patel R, Wall R, et al. Variation in the genetic environments of bla(CTX-M-15) in Escherichia coli from the faeces of travellers returning to the United Kingdom. J Antimicrob Chemother 2011;66:1005-12.
152. Kim J, Bae IK, Jeong SH, et al. Characterization of IncF plasmids carrying the blaCTX-M-14 gene in clinical isolates of Escherichia coli from Korea. J Antimicrob Chemother 2011;66:1263-8.
153. van der Bij AK, Peirano G, Goessens WHF, et al. Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands. Antimicrob Agents Chemother 2011;55:3576-8.
154. Titelman E, Karlsson IM, Ge Y, et al. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011;70:137-41.
155. Cao X, Cavaco LM, Lv Y, et al. Molecular characterization and antimicrobial susceptibility testing of Escherichia coli isolates from patients with urinary tract infections in 20 Chinese hospitals. J Clin Microbiol 2011;49:2496-501.
156. Mshana SE, Imirzalioglu C, Hain T, et al. Multiple ST clonal complexes, with a predominance of ST131, of Escherichia coli harbouring blaCTX-M-15 in a tertiary hospital in Tanzania. Clin Microbiol Infect 2011;17:1279-82.
157. Blanco J, Mora A, Mamani R, et al. National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother 2011;66:2011-21.
158. Shin J, Kim DH, Ko KS. Comparison of CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae isolates from patients with bacteremia. J Infect 2011;63:39-47.
159. Croxall G, Hale J, Weston V, et al. Molecular epidemiology of extraintestinal pathogenic Escherichia coli isolates from a regional cohort of elderly patients highlights the prevalence of ST131 strains with increased antimicrobial resistance in both community and hospital care settings. J Antimicrob Chemother 2011;66:2501-8.
160. Simner PJ, Hoban DJ, Lagacé-Wiens PRS, et al. Fluoroquinolone resistance in Escherichia coli isolated from patients attending Canadian hospitals is associated with the ST131 clone. Diagn Microbiol Infect Dis 2011;71:323-4.
161. Titelman E, Iversen A, Kahlmeter G, et al. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 2011;119:853-63.
162. Molina-López J, Aparicio-Ozores G, Ribas-Aparicio RM, et al. Drug resistance, serotypes, and phylogenetic groups among uropathogenic Escherichia coli including O25-ST131 in Mexico City. J Infect Dev Ctries 2011;5:840-9. http://www.ncbi.nlm.nih.gov/ pubmed/22169782 (accessed 20 May 2015).
163. Sidjabat HE, Derrington P, Nimmo GR, et al. Escherichia coli ST131 producing CTX-M-15 in Australia. J Antimicrob Chemother 2010;65:1301-3.
164. Tian GB, Garcia J, Adams-Haduch JM, et al. CTX-M as the predominant extended-spectrum beta-lactamases among Enterobacteriaceae in Manila, Philippines. J Antimicrob Chemother 2010;65:584-6.
165. Platell JL, Cobbold RN, Johnson JR, et al. Clonal group distribution of fluoroquinolone-resistant Escherichia coli among humans and companion animals in Australia. J Antimicrob Chemother 2010;65:1936-8.
166. Naseer U, Haldorsen B, Simonsen GS, et al. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 2010;16:171-8.
167. Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients. Antimicrob Agents Chemother 2010;54:546-50.
168. Lee MY, Choi HJ, Choi JY, et al. Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea. J Infect 2010;60:146-53.
169. Peirano G, Richardson D, Nigrin J, et al. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother 2010;54:1327-30.
170. Severin JA, Mertaniasih NM, Kuntaman K, et al. Molecular characterization of extended-spectrum beta-lactamases in clinical Escherichia coli and Klebsiella pneumoniae isolates from Surabaya, Indonesia. J Antimicrob Chemother 2010;65:465-9.
171. Cerquetti M, Giufrè M, García-Fernández A, et al. Ciprofloxacin-resistant, CTX-M-15-producing Escherichia coli ST131 clone in extraintestinal infections in Italy. Clin Microbiol Infect 2010;16:1555-8.
172. Peirano G, Costello M, Pitout JDD. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: High prevalence of ST131 producing CTX-M-15 in community hospitals. Int J Antimicrob Agents 2010;36:19-23.
173. Smet A, Martel A, Persoons D, et al. Characterization of extended-spectrum beta-lactamases produced by Escherichia coli isolated from hospitalized and nonhospitalized patients: Emergence of CTX-M-15-producing strains causing urinary tract infections. Microb Drug Resist 2010;16:129-34.
174. Dahmen S, Bettaieb D, Mansour W, et al. Characterization and molecular epidemiology of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in a Tunisian University Hospital. Microb Drug Resist 2010;16:163-70.
175. Oteo J, Cercenado E, Cuevas O, et al. AmpC beta-lactamases in Escherichia coli: Emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis 2010;67:270-6.
176. D?az MA, Hernandez-Bello JR, Rodr?guez-Ba?o J, et al, Spanish Group for Nosocomial Infections (GEIH). Diversity of Escherichia coli strains producing extended-spectrum ß-lactamases in Spain: Second nationwide study. J Clin Microbiol 2010;48:2840-5.
177. Bert F, Johnson JR, Ouattara B, et al. Genetic diversity and virulence profiles of Escherichia coli isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. J Clin Microbiol 2010;48:2709-14.
178. Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010;51:286-94.
179. Vidal-Navarro L, Pfeiffer C, Bouziges N, et al. Faecal carriage of multidrug-resistant Gram-negative bacilli during a non-outbreak situation in a French university hospital. J Antimicrob Chemother 2010;65:2455-8.
180. Brolund A, H?ggman S, Edquist PJ, et al. The DiversiLab system versus pulsed-field gel electrophoresis: Characterisation of extended spectrum ß-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Microbiol Methods 2010;83:224-30.
181. Jouini A, Ben Slama K, Vinué L, et al. Detection of unrelated Escherichia coli strains harboring genes of CTX-M-15, OXA-1, and AAC(6')-Ib-cr enzymes in a Tunisian hospital and characterization of their integrons and virulence factors. J Chemother 2010;22:318-23.
182. Pitout JDD, Campbell L, Church DL, et al. Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother 2009;53:2539-43.
183. Morris D, Boyle F, Buckley V, et al. CTX-M enzymes are the predominant extended-spectrum beta-lactamases produced by Enterobacteriaceae in Ireland. J Antimicrob Chemother 2009;64:864-6.
184. Hrabak J, Empel J, Bergerova T, et al. International clones of Klebsiella pneumoniae and Escherichia coli with extended-spectrum ß-lactamases in a Czech Hospital. J Clin Microbiol 2009;47:3353-7.
185. Suzuki S, Shibata N, Yamane K, et al. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 2009;63:72-9.
186. Literacka E, Bedenic B, Baraniak A, et al. blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. Antimicrob Agents Chemother 2009;53:1630-5.
187. Pitout JDD, Campbell L, Church DL, et al. Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. J Clin Microbiol 2009;47:1212-15.
188. Arpin C, Quentin C, Grobost F, et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009;63:1205-14.
189. Blanco M, Alonso MP, Nicolas-Chanoine MH, et al. Molecular epidemiology of Escherichia coli producing extended-spectrum (beta)-lactamases in Lugo (Spain): Dissemination of clone O25b: H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2009;63:1135-41.
190. Pitout JDD, Gregson DB, Campbell L, et al. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009;53:2846-51.
191. Johnson JR, Menard M, Johnston B, et al. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009;53:2733-9.
192. Oteo J, Diestra K, Juan C, et al. Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents 2009;34:173-6.
193. Clermont O, Dhanji H, Upton M, et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009;64:274-7.
194. Naseer U, Haldorsen B, Tofteland S, et al. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009;117:526-36.
195. Oteo J, Orden B, Bautista V, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009;64:712-17.
196. Sidjabat HE, Paterson DL, Adams-Haduch JM, et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother 2009;53:4733-9.
197. Lau SH, Reddy S, Cheesbrough J, et al. Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing. J Clin Microbiol 2008;46:1076-80.
198. Yumuk Z, Afacan G, Nicolas-Chanoine MH, et al. Turkey: A further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother 2008;62:284-8.
199. Cagnacci S, Gualco L, Debbia E, et al. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 2008;46:2605-12.
200. Jones GL, Warren RE, Skidmore SJ, et al. Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extended-spectrum beta-lactamases. J Antimicrob Chemother 2008;62:1245-51.
201. Fam NS, Defasque S, Bert F, et al. Faecal carriage of extended-spectrum ß-lactamase (ESBL)-producing enterobacteria in liver disease patients from two hospitals in Egypt and France: A comparative epidemiological study. Epidemiol Infect 2015;143:1247-55.
202. Liss MA, Johnson JR, Porter SB. Clinical and microbiological determinants of infection after transrectal prostate biopsy. Clin Infect Dis 2015;60:979-87.
203. Valverde A, Turrientes MC, Norman F, et al. CTX-M-15-non-ST131 Escherichia coli isolates are mainly responsible of faecal carriage with ESBL-producing Enterobacteriaceae in travellers, immigrants and those visiting friends and relatives. Clin Microbiol Infect 2015;21:252.e1-4.
204. Stewardson AJ, Renzi G, Maury N, et al. Extended-spectrum ß-lactamase-producing Enterobacteriaceae in hospital food: A risk assessment. Infect Control Hosp Epidemiol 2014;35:375-83.
205. Yaita K, Aoki K, Suzuki T, et al. Epidemiology of extended-spectrum ß-lactamase producing Escherichia coli in the stools of returning Japanese travelers, and the risk factors for colonization. PLoS ONE 2014;9:e98000.
206. Lupindu AM, Olsen JE, Ngowi HA, et al. Occurrence and characterization of Shiga toxin-producing Escherichia coli O157:H7 and other non-sorbitol-fermenting E. coli in cattle and humans in urban areas of Morogoro, Tanzania. Vector Borne Zoonotic Dis 2014;14:503-10.
207. Vervoort J, Gazin M, Kazma M, et al. High rates of intestinal colonisation with fluoroquinolone-resistant ESBL-harbouring Enterobacteriaceae in hospitalised patients with antibiotic-associated diarrhoea. Eur J Clin Microbiol Infect Dis 2014;33:2215-21.
208. Han JH, Johnston B, Nachamkin I, et al. Clinical and molecular epidemiology of Escherichia coli sequence type 131 among hospitalized patients colonized intestinally with fluoroquinolone-resistant E. coli. Antimicrob Agents Chemother 2014;58:7003-6.
209. Vasoo S, Madigan T, Cunningham SA, et al. Prevalence of rectal colonization with multidrug-resistant Enterobacteriaceae among international patients hospitalized at Mayo Clinic, Rochester, Minnesota. Infect Control Hosp Epidemiol 2014;35:182-6.
210. March A, Aschbacher R, Pagani E, et al. Changes in colonization of residents and staff of a long-term care facility and an adjacent acute-care hospital geriatric unit by multidrug-resistant bacteria over a four-year period. Scand J Infect Dis 2014;46:114-22.
211. Nicolas-Chanoine MH, Gruson C, Bialek-Davenet S, et al. 10-Fold increase (2006-11) in the rate of healthy subjects with extended-spectrum ß-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. J Antimicrob Chemother 2013;68:562-8.
212. Izdebski R, Baraniak A, Fiett J, et al, MOSAR WP2 and WP5 Study Groups. Clonal structure, extended-spectrum ß-lactamases, and acquired AmpC-type cephalosporinases of Escherichia coli populations colonizing patients in rehabilitation centers in four countries. Antimicrob Agents Chemother 2013;57:309-16.
213. Liss MA, Peterson EM, Johnston B, et al. Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. Urology 2013;81:548-55.
214. Birgy A, Mariani-Kurkdjian P, Bidet P, et al. Characterization of extended-spectrum-beta-lactamase-producing Escherichia coli strains involved in maternal-fetal colonization: Prevalence of E. coli ST131. J Clin Microbiol 2013;51:1727-32.
215. Nüesch-Inderbinen MT, Abgottspon H, Zurfluh K, et al. Cross-sectional study on fecal carriage of Enterobacteriaceae with resistance to extended-spectrum cephalosporins in primary care patients. Microb Drug Resist 2013;19:362-9.
216. Arvand M, Moser V, Pfeifer Y. Prevalence of extended-spectrum-ß- lactamase-producing Escherichia coli and spread of the epidemic clonal lineage ST131 in nursing homes in Hesse, Germany. J Antimicrob Chemother 2013;68:2686-8.
217. Roy S, Krishnan R, Mukherjee S, et al. Prevalence of ST131 virulence-associated strains among CTX-M-producing Escherichia coli in the gut of hospitalized neonates in India. Diagn Microbiol Infect Dis 2013;77:158-9.
218. Severin JA, Lestari ES, Kloezen W, et al. Faecal carriage of extended-spectrum ß-lactamase-producing Enterobacteriaceae among humans in Java, Indonesia, in 2001-2002. Trop Med Int Health 2012;17:455-61.
219. Dolejska M, Brhelova E, Dobiasova H, et al. Dissemination of IncFII(K)-type plasmids in multiresistant CTX-M-15-producing Enterobacteriaceae isolates from children in hospital paediatric oncology wards. Int J Antimicrob Agents 2012;40:510-15.
220. Li B, Sun JY, Liu QZ, et al. High prevalence of CTX-M ß-lactamases in faecal Escherichia coli strains from healthy humans in Fuzhou, China. Scand J Infect Dis 2011;43:170-4.
221. Peirano G, Laupland KB, Gregson DB, et al. Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med 2011;18:299-303.
222. Leflon-Guibout V, Blanco J, Amaqdouf K, et al. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008;46:3900-5.
223. Diago-Navarro E, Chen L, Passet V, et al. Carbapenem-resistant Klebsiella pneumoniae exhibit variability in capsular polysaccharide and capsule associated virulence traits. J Infect Dis 2014;210:803-13.
224. van Duin D, Perez F, Rudin SD, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: Tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014;58:4035-41.
225. Mezzatesta ML, Caio C, Gona F, et al. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: Considerations on in vitro assay of active drugs. Int J Antimicrob Agents 2014;44:112-16.
226. Ageevets VA, Partina IV, Lisitsyna ES, et al. Emergence of carbapenemase-producing Gram-negative bacteria in Saint Petersburg, Russia. Int J Antimicrob Agents 2014;44:152-5.
227. Tijet N, Sheth PM, Lastovetska O, et al. Molecular characterization of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae in Ontario, Canada, 2008-2011. PLoS ONE 2014;9:e116421.
228. Hrabák J, Papagiannitsis CC, Študentová V, et al. Carbapenemase-producing Klebsiella pneumoniae in the Czech Republic in 2011. Euro Surveill 2013;18:20626. http://www.ncbi. nlm.nih.gov/pubmed/24229789 (accessed 20 May 2015).
229. Lascols C, Peirano G, Hackel M, et al. Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: First report of OXA-48-like enzymes in North America. Antimicrob Agents Chemother 2013;57:130-6.
230. Castanheira M, Farrell SE, Wanger A, et al. Rapid expansion of KPC-2-producing Klebsiella pneumoniae isolates in two Texas hospitals due to clonal spread of ST258 and ST307 lineages. Microb Drug Resist 2013;19:295-7.
231. Rodríguez-Zulueta P, Silva-Sánchez J, Barrios H, et al. First outbreak of KPC-3-producing Klebsiella pneumoniae (ST258) clinical isolates in a Mexican Medical Center. Antimicrob Agents Chemother 2013;57:4086-8.
232. Di Carlo P, Gulotta G, Casuccio A, et al. KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: Analysis of a case series of 30 patients. BMC Anesthesiol 2013;13:13.
233. Jain R, Walk ST, Aronoff DM, et al. Emergence of Carbapenemaseproducing Klebsiella Pneumoniae of Sequence type 258 in Michigan, USA. Infect Dis Rep 2013;5:e5.
234. Cejas D, Fernandez Canigia L, Nastro M, et al. Hyperendemic clone of KPC producing Klebsiellapneumoniae ST 258 in Buenos Aires hospitals. Infect Genet Evol 2012;12:499-501.
235. Warburg G, Hidalgo-Grass C, Partridge SR, et al. A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: Sequence type 512 carrying a plasmid encoding aac (6')-Ib. J Antimicrob Chemother 2012;67:898-901.
236. Richter SN, Frasson I, Franchin E, et al. KPC-mediated resistance in Klebsiella pneumoniae in two hospitals in Padua, Italy, June 2009-December 2011: Massive spreading of a KPC-3-encoding plasmid and involvement of non-intensive care units. Gut Pathog 2012;4:7.
237. Adler A, Paikin S, Sterlin Y, et al. A swordless knight: Epidemiology and molecular characteristics of the blaKPC-negative sequence type 258 Klebsiella pneumoniae clone. J Clin Microbiol 2012;50:3180-5.
238. Mammina C, Bonura C, Di Bernardo F, et al. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill 2012;17:pii: 20248. http://www.ncbi.nlm.nih.gov/pubmed/22913977 (accessed 20 May 2015).
239. Mataseje LF, Boyd DA, Willey BM, et al. Plasmid comparison and molecular analysis of Klebsiella pneumoniae harbouring bla(KPC) from New York City and Toronto. J Antimicrob Chemother 2011;66:1273-7.
240. Giakkoupi P, Papagiannitsis CC, Miriagou V, et al. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10). J Antimicrob Chemother 2011;66:1510-13.
241. Andrade LN, Curiao T, Ferreira JC, et al. Dissemination of blaKPC-2 by the spread of Klebsiella pneumoniae clonal complex 258 clones (ST258, ST11, ST437) and plasmids (IncFII, IncN, IncL/M) among Enterobacteriaceae species in Brazil. Antimicrob Agents Chemother 2011;55:3579-83.
242. Gomez SA, Pasteran FG, Faccone D, et al. Clonal dissemination of Klebsiella pneumoniae ST258 harbouring KPC-2 in Argentina. Clin Microbiol Infect 2011;17:1520-4.
243. Baraniak A, Grabowska A, Izdebski R, et al. Molecular characteristics of KPC-producing Enterobacteriaceae at the early stage of their dissemination in Poland, 2008-2009. Antimicrob Agents Chemother 2011;55:5493-9.
244. Cuzon G, Naas T, Truong H, et al. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis 2010;16:1349-56.
245. Endimiani A, Depasquale JM, Forero S, et al. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: A new challenge to our healthcare system. J Antimicrob Chemother 2009;64:1102-10.
246. Paterson GK, Harrison EM, Murray GGR, et al. Capturing the cloud of diversity reveals complexity and heterogeneity of MRSA carriage, infection and transmission. Nat Commun 2015;6:6560.